LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN IBD: A META-ANALYSIS OF REAL-WORLD AND RANDOMIZED DATA

作者：Prince Shah-riar, Nowrin Tamanna, Umme Kulsum, A. Gould, Asif Zamir · 发表于：Inflammatory Bowel Diseases · 年份：2026 · DOI：10.1093/ibd/izag006.121 · 被引用次数：1

Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, often necessitates long-term therapy to achieve and maintain remission. While biologics have transformed disease control, their long-term comparative effectiveness and safety across drug classes remain insufficiently synthesized. Most existing data are from controlled trials with limited external validity. This study aimed to evaluate long-term clinical outcomes of biologic therapies in IBD using real-world and randomized controlled data, focusing on remission, mucosal healing, steroid independence, and adverse event profiles. We conducted a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials (RCTs) and real-world cohort studies from 2020–2022. Databases searched included PubMed (n = 796), Cochrane (n = 403), ClinicalTrials.gov (n = 361), and Google Scholar (n = 64). Inclusion criteria were: (1) adult IBD patients treated with biologics, (2) ≥12 months follow-up, (3) sample size ≥50. Outcomes included clinical remission, mucosal healing, steroid-free remission, and serious adverse events (SAEs). Of 1,620 studies identified, 23 were eligible for quantitative synthesis. Data were pooled using a random-effects model. Risk of bias was assessed via Cochrane ROB-2. Among 7,842 patients across 23 studies: • 12-month Clinical Remission: Achieved in 58% of patients (pooled RR 1.61; 95% CI: 1.34–1.94; I2 = 29%) • Mucosal Healing: Achieved in 46% (R...